Day: February 19, 2025

Ensurge Micropower ASA – Q4 2024

Written by Customer Service on February 19, 2025. Posted in Earnings Releases And Operating Results.

HighlightsMicrobattery energy leakage issue close to being solved In advanced discussions about a joint development agreement with a Fortune 500 company for the next generation batteries significantly increasing energy density 24/7 shift structure implemented to enable production ramp-up Resolved the battery stack encapsulation issues through process optimization and material selection Achieved 90% stacking yield after cell test for both 11- and 28-layer batteries, and are therefore confident in both repeatability and scalability of the production process The batteries meet — and even exceed — stringent requirements for quality, durability, and scalability of the production process Growing pipeline of customers Continued strong collaboration with our strategic partners Issued five Invention Disclosure Records...

2024: A record-breaking performance paving the way for 2025-2028 strategic roadmap

Written by Customer Service on February 19, 2025. Posted in Earnings Releases And Operating Results.

2024: A record-breaking performance Paving the way for 2025-2028 strategic roadmap _PRESS RELEASE_2024 standard sales of €7.1 billion (current sales of €8.5 billion), up +8.7% on a reported basis and +5.1% organicallyAcceleration in Electrification businesses, up +13.0% organically in 2024, reflecting early-bird investment and unabated focus on value-added solutions Q4 2024 standard sales of €1.9 billion, up +8.3% organically driven by all businessesA performance-driven journey beyond 2024 objectives and “Winds of Change” 2021-2024 Capital Markets Day targets:All-time high adjusted EBITDA of €804 million, up +21.0% year-on-year, and adjusted EBITDA margin at 11.4% Outstanding Normalized free cash flow at €454 million and 56% normalized cash conversion Outperformance of ROCE in Electrification businesses at 26.3%...

Strong revenue growth, margin expansion and FCF delivery in 2024, while investing significantly and reaching key transformation milestones

Written by Customer Service on February 19, 2025. Posted in Earnings Releases And Operating Results.

Regulated informationPortfolio refocus nearly complete and major steps taken in transforming European and North American footprint; Innovation and operating efficiencies strengthened competitiveness, leading to 6% volume & mix growth and 28% adj. EBITDA increase; Solid operational result facilitated step up of investments in transformation and growth, while raising FCF to €48 million; 2025 outlook for revenue to grow by 3% to 5% LFL, adj. EBITDA by 4% to 7%, and FCF to remain strong;CEO quote Gustavo Calvo Paz, Ontex’s CEO, said: “We achieved key strategic milestones last year, thanks to the dedication of Ontex’s teams. With all planned strategic divestments finalized or agreed, we will be fully focused on retailer and healthcare brands by end 2025. We also achieved a major step to make our European footprint leaner, with the...

Wix Reports Fourth Quarter and Full Year 2024 Results

Written by Customer Service on February 19, 2025. Posted in Earnings Releases And Operating Results.

Capping off a year of sustained growth acceleration and stronger than expected FCF generation – surpassing Rule of 40 in 2024 and on track to achieve Rule of 45 in 2025Culminated a year of accelerated growth and innovation with Q4 bookings of $465 million, up 18% y/y, and Q4 revenue of $460 million, up 14% y/ySteady growth acceleration in Self Creators coupled with continued strength in high-growth Partners, demonstrated by Partners revenue growth of 30% y/y in FY2024 Strong momentum across key product focus areas, including Studio, AI and commerce as well as solid business fundamentals and price increase benefitRobust growth and a stable operating cost base drove FCF1 generation to nearly double in 2024 compared to previous year, resulting in continued profitability improvement with Q4 FCF margin of 29% and full year FCF1 margin...

MARIMEKKO FINANCIAL STATEMENTS BULLETIN, 1 Jan–31 Dec 2024: Marimekko’s net sales in the fourth quarter grew and operating profit improved

Written by Customer Service on February 19, 2025. Posted in Earnings Releases And Operating Results.

Marimekko Corporation, Financial Statements Bulletin, 19 February 2025 at 8.00 a.m. EET MARIMEKKO FINANCIAL STATEMENTS BULLETIN, 1 Jan–31 Dec 2024: Marimekko’s net sales in the fourth quarter grew and operating profit improved This release is a summary of Marimekko’s financial statements bulletin for the January-December period of 2024. The complete report is attached to this release as a pdf file and it is also available on the company’s website at company.marimekko.com under Releases & publications. The fourth quarter in briefMarimekko’s net sales increased by 7 percent and totaled EUR 54.0 million (50.6). Net sales were boosted, in particular, by the increased retail sales in all market areas. Net sales in Finland grew by 3 percent as domestic retail sales developed well, increasing by 8 percent. International sales grew by 13...

Philips delivers growth, improved profitability, and strong cash flow in Q4 and 2024; continues solid execution of its three-year plan

Written by Customer Service on February 19, 2025. Posted in Earnings Releases And Operating Results.

February 19, 2025 Full Year and Q4 Group performance highlightsSales of EUR 18.0 billion in 2024, comparable sales growth 1%; EUR 5.0 billion in Q4, comparable sales growth 1%, despite double-digit decline in China Comparable order intake increased 1% in 2024; up 2% in Q4, despite double-digit decline in China Income from operations was EUR 529 million in 2024; EUR 199 million in Q4 Adjusted EBITA margin increased 90 basis points to 11.5% of sales in 2024; up 60 basis points to 13.5% in Q4 Net cash flow from operating activities was EUR 1,569 million in 2024; EUR 1,459 million in Q4 Free cash flow was EUR 906 million in 2024; EUR 1,285 million in Q4 Finalized Philips Respironics recall-related medical monitoring and personal injury settlements in US Proposed dividend maintained at EUR 0.85 per share, in shares or cash Increased productivity...

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Written by Customer Service on February 19, 2025. Posted in Public Companies.

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in the Middle East, marked by the first successful Genio implant performed at Saudi German Hospital, Dubai – United Arab Emirates. The first patient was successfully implanted by Dr. Ahmed Yassin Bahgat, Consultant Otolaryngologist at Saudi German Hospital. Reflecting on this milestone, Dr. Bahgat stated: “We are honored...

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Written by Customer Service on February 19, 2025. Posted in Public Companies.

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates Mont-Saint-Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in the Middle East, marked by the first successful Genio implant performed at Saudi German Hospital, Dubai – United Arab Emirates, supported by Odin Healthcare – partnering with Nyxoah in the region. The first patient was successfully implanted by Dr. Ahmed Yassin Bahgat, Consultant Otolaryngologist at Saudi German Hospital. Reflecting...

Philips proposes new Supervisory Board appointments and reappointments, and Board of Management reappointment

Written by Customer Service on February 19, 2025. Posted in Public Companies.

Mr David PyottMr Bob WhiteMs Indra NooyiMs Chua Sock KoongMr Marnix van GinnekenMr David Pyott to retire from Philips’ Supervisory Board after his third consecutive term. Mr Bob White proposed as new member of the Supervisory Board. Ms Indra Nooyi and Ms Chua Sock Koong proposed for reappointment as members of the Supervisory Board. Mr Marnix van Ginneken proposed for reappointment as member of Philips’ Board of Management.February 19, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced proposed Supervisory Board appointments and reappointments, and a proposed Board of Management reappointment. Mr David Pyott (British/American, 1953) will retire from Philips’ Supervisory Board at the end of the Annual General Meeting...

Vopak announces share buyback program to return up to EUR 100 million to shareholders

Written by Customer Service on February 19, 2025. Posted in Public Companies.

Vopak announces share buyback program to return up to EUR 100 million to shareholders Rotterdam, the Netherlands, 19th February 2025 Today, Vopak announces the start of a share buyback program to return up to EUR 100 million to shareholders. The share buyback program will start 20 February 2025 and will run until the end of 2025, barring unforeseen circumstances. Vopak will cancel these shares subject to the relevant board and shareholder approvals. The share buyback program will be executed pursuant to the safe harbour regime of the Market Abuse Regulation and under the existing authority granted at the 2024 Annual General Meeting on 24 April 2024, and, subsequently, the authority (if granted) by the 2025 Annual General Meeting on 23 April 2025. Under these limits the share buyback program shall not exceed 10% of Vopak’s issued capital. The...

Day: February 19, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals